Hematologic Malignancy
Myelodysplastic/Myeloproliferative Neoplasm
CI-CAN-00001250Explore in graph →
Hematologic115 active trials3 approved drugs6 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00001250Explore in graph →
Clinical trials
528 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (77)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02257138 | Ruxolitinib Phosphate and Decitabine in Treating Patients With Relapsed or Refractory or Post Myeloproliferative Acute Myeloid Leukemia | completed | Phase 1 / Phase 2 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 8, 2025 | clinicaltrials |
| NCT02397720 | Nivolumab and Azacitidine With or Without Ipilimumab in Treating Patients With Refractory/Relapsed or Newly Diagnosed Acute Myeloid Leukemia | completed | Phase 2 | 150 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 8, 2025 |
| clinicaltrials |
| NCT04752163 | DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia | terminated | Phase 1 / Phase 2 | 17 | M.D. Anderson Cancer CenterOTHER | 1 | May 23, 2025 | clinicaltrials |
| NCT03066648 | Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS | completed | Phase 1 | 241 | Novartis PharmaceuticalsINDUSTRY | 8 | May 18, 2025 | clinicaltrials |
| NCT04730258 | A Study of CFI-400945 With or Without Azacitidine in Patients With AML, MDS or CMML(TWT-202) | active not recruiting | Phase 1 / Phase 2 | 72 | Treadwell Therapeutics, IncINDUSTRY | 3 | May 18, 2025 | clinicaltrials |
| NCT02566304 | Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies | completed | Phase 2 | 35 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Apr 24, 2025 | clinicaltrials |
| NCT04487106 | Azacitidine, Venetoclax, and Trametinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome | completed | Phase 2 | 21 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 22, 2025 | clinicaltrials |
| NCT06355583 | Intestinal Microbiota Transplant Prior to Allogeneic Stem Cell Transplant (MAST) Trial(MAST) | recruiting | Phase 2 | 50 | Imperial College LondonOTHER | 1 | Apr 17, 2025 | clinicaltrials |
| NCT06462365 | Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT) | recruiting | Phase 1 | 36 | Tr1X, Inc.INDUSTRY | 1 | Apr 15, 2025 | clinicaltrials |
| NCT01892371 | Quizartinib With Azacitidine or Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome | completed | Phase 1 / Phase 2 | 73 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 6, 2025 | clinicaltrials |
| NCT00588991 | Veliparib and Topotecan With or Without Carboplatin in Treating Patients With Relapsed or Refractory Acute Leukemia, High-Risk Myelodysplasia, or Aggressive Myeloproliferative Disorders | completed | Phase 1 | 12 | National Cancer Institute (NCI)NIH | 1 | Apr 2, 2025 | clinicaltrials |
| NCT06900088 | Selinexor Combined With Azacitidine Therapy in High-Risk Myeloid Neoplasms Patients | not yet recruiting | Phase 2 | 20 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Mar 28, 2025 | clinicaltrials |
| NCT02193958 | Study of FF-10501-01 in Patients With Relapsed or Refractory Hematological Malignancies | completed | Phase 1 / Phase 2 | 55 | Fujifilm Pharmaceuticals U.S.A., Inc.INDUSTRY | 1 | Mar 19, 2025 | clinicaltrials |
| NCT04372433 | IO-202 as Monotherapy and IO-202 Plus Azacitidine ± Venetoclax in Patients in AML and CMML | completed | Phase 1 | 67 | Immune-Onc TherapeuticsINDUSTRY | 1 | Feb 14, 2025 | clinicaltrials |
| NCT05030675 | Fostamatinib for the Treatment of Lower-risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia Who Have Failed Therapy With Hypomethylating Agents | completed | Phase 1 | 11 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 13, 2025 | clinicaltrials |
| NCT01261312 | SGI-110 in Participants With Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML) | completed | Phase 1 / Phase 2 | 414 | Astex Pharmaceuticals, Inc.INDUSTRY | 2 | Jan 23, 2025 | clinicaltrials |
| NCT05488548 | Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors and Hematological Malignancies | recruiting | Phase 1 | 75 | Epigenetix, Inc.INDUSTRY | 1 | Jan 14, 2025 | clinicaltrials |
| NCT02268253 | Tagraxofusp (SL-401) in Participants With Chronic Myelomonocytic Leukemia (CMML) and Myelofibrosis (MF) | completed | Phase 1 / Phase 2 | 82 | Stemline Therapeutics, Inc.INDUSTRY | 2 | Jan 6, 2025 | clinicaltrials |
| NCT04522895 | IDH2-Post-Allo-Trial for Patients with IDH2-mut Myeloid Neoplasms After Allo-SCT | completed | Phase 2 | 50 | Heinrich-Heine University, DuesseldorfOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT02760238 | Myeloproliferative Neoplasms (MPNs) Patient Registry | recruiting | — | 5,000 | University Health Network, TorontoOTHER | 1 | Aug 27, 2024 | clinicaltrials |
| NCT03306264 | Study of ASTX727 vs IV Decitabine in Participants With MDS, CMML, and AML | completed | Phase 3 | 227 | Astex Pharmaceuticals, Inc.INDUSTRY | 10 | Aug 27, 2024 | clinicaltrials |
| NCT03813186 | Effect of Food on Blood Levels of ASTX727 | completed | Phase 1 | 18 | Astex Pharmaceuticals, Inc.INDUSTRY | 1 | Aug 2, 2024 | clinicaltrials |
| NCT04637009 | A Study of TAS1553 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML) and Other Myeloid Neoplasms | terminated | Phase 1 | 20 | Astex Pharmaceuticals, Inc.INDUSTRY | 2 | Aug 2, 2024 | clinicaltrials |
| NCT06111612 | Intensive Conditioning withTHI/Bu/Flu/Ara-C in Allo-HSCT for Myeloid Malignancies With Extramedullary Involvement | recruiting | — | 50 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | Jul 22, 2024 | clinicaltrials |
| NCT02061800 | CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant | unknown | Phase 1 / Phase 2 | 14 | Diane GeorgeOTHER | 1 | Jun 4, 2024 | clinicaltrials |
| NCT03493646 | Evaluating in Vivo AZA Incorporation in Mononuclear Cells Following Vidaza or CC486 | completed | Phase 2 | 40 | Kirby InstituteOTHER_GOV | 1 | May 28, 2024 | clinicaltrials |
| NCT03047993 | Glutaminase Inhibitor CB-839 and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndrome | completed | Phase 1 / Phase 2 | 28 | M.D. Anderson Cancer CenterOTHER | 1 | May 14, 2024 | clinicaltrials |
| NCT06218628 | Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition | recruiting | Phase 1 | 24 | Fox Chase Cancer CenterOTHER | 1 | May 3, 2024 | clinicaltrials |
| NCT05895201 | High-Dose Post-Transplant Cyclophosphamide, Bortezomib, and Sitagliptin for the Prevention of GVHD | withdrawn | Phase 1 / Phase 2 | 0 | Indiana UniversityOTHER | 1 | Apr 29, 2024 | clinicaltrials |
| NCT03682029 | Epigenetics, Vitamin C, and Abnormal Blood Cell Formation - Vitamin C in Patients With Low-Risk Myeloid Malignancies(EVITA) | unknown | N/A | 109 | Rigshospitalet, DenmarkOTHER | 2 | Apr 17, 2024 | clinicaltrials |
| NCT03999723 | Combining Active and Passive DNA Hypomethylation(EVI-3) | recruiting | Phase 2 | 196 | Kirsten GrønbækOTHER | 2 | Apr 17, 2024 | clinicaltrials |
| NCT01588015 | Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant | completed | Phase 1 | 36 | City of Hope Medical CenterOTHER | 1 | Apr 2, 2024 | clinicaltrials |
| NCT01595295 | Registry on Hypomethylating Agents in Myeloid Neoplasms | completed | — | 1,500 | Arbeitsgemeinschaft medikamentoese TumortherapieOTHER | 2 | Mar 25, 2024 | clinicaltrials |
| NCT06085638 | Phase I/II Study of SY-1425 (Tamibarotene) in Combination With Azacitidine and Venetoclax for Patients With Chronic Myelomonocytic Leukemia | withdrawn | Phase 1 / Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Mar 7, 2024 | clinicaltrials |
| NCT03878524 | Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial | terminated | Phase 1 | 2 | OHSU Knight Cancer InstituteOTHER | 1 | Mar 4, 2024 | clinicaltrials |
| NCT06267898 | Non Interventional Study on Iron Toxicity After First Allo-transplant in MDS/CMML | completed | — | 222 | European Society for Blood and Marrow TransplantationNETWORK | 3 | Feb 20, 2024 | clinicaltrials |
| NCT01812252 | Chemotherapy in Treating Patients With Myelodysplastic Syndrome Before Donor Stem Cell Transplant(ICT-HCT) | completed | Phase 2 | 50 | Fred Hutchinson Cancer CenterOTHER | 1 | Feb 15, 2024 | clinicaltrials |
| NCT04358393 | A Study of APG-115 Alone or Combined With Azacitidine in Patients With AML, CMML, or MDS | unknown | Phase 1 / Phase 2 | 69 | Ascentage Pharma Group Inc.INDUSTRY | 1 | Feb 1, 2024 | clinicaltrials |
| NCT05107856 | PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies | terminated | Phase 1 | 21 | Prelude TherapeuticsINDUSTRY | 1 | Jan 31, 2024 | clinicaltrials |
| NCT02367456 | A Combination Study of PF-04449913 (Glasdegib) and Azacitidine In Untreated MDS, AML and CMML Patients(BRIGHT 1012) | completed | Phase 1 | 73 | PfizerINDUSTRY | 6 | Jan 19, 2024 | clinicaltrials |
| NCT06211166 | Assessment of Measurable Residual Disease in Allo-HSCT Using Digital Polymerase Chain Reaction | recruiting | — | 300 | Peking University People's HospitalOTHER | 1 | Jan 18, 2024 | clinicaltrials |
| NCT03734601 | Total Body Irradiation +/- Total Lymphoid Irradiation & Anti-Thymocyte Globulin in Non-myeloablative Hematopoietic Cell Transplantation | completed | Phase 2 | 22 | Stanford UniversityOTHER | 1 | Dec 12, 2023 | clinicaltrials |
| NCT00167219 | Stem Cell Transplant for Juvenile Myelomonocytic Leukemia (JMML) | completed | Phase 1 / Phase 2 | 15 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Nov 7, 2023 | clinicaltrials |
| NCT01823198 | Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients With High Risk Myeloid Malignancies | completed | Phase 1 / Phase 2 | 63 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 7, 2023 | clinicaltrials |
| NCT01404741 | 5-azacytidine Treatment Versus 5-azacytidine Followed by Allogeneic Stem Cell Transplantation in Elderly Patients With Myelodysplastic Syndrome (MDS) | completed | Phase 2 | 191 | Universitätsklinikum Hamburg-EppendorfOTHER | 1 | Oct 27, 2023 | clinicaltrials |
| NCT06098313 | HCT With PTCy in Higher-risk MDS | active not recruiting | Phase 2 | 113 | Asan Medical CenterOTHER | 1 | Oct 24, 2023 | clinicaltrials |
| NCT00611351 | Busulfan, Cyclophosphamide, & Antithymocyte Globulin Followed by Stem Cell Transplant in Treating Hematologic Cancer | completed | Phase 2 | 5 | University of NebraskaOTHER | 1 | Oct 23, 2023 | clinicaltrials |
| NCT05048498 | Pharmacokinetics, Tolerability and Safety of NEX-18a | completed | Phase 1 | 2 | Nanexa ABINDUSTRY | 1 | Oct 17, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Jun 8, 2025source: clinicaltrials